The Investment Column: Cash-rich Amec is keen to engineer acquisitions

Galliford Try; Phytopharm


Our view: Buy

Share price: 849.5p (+23p)

According to the engineering group Amec's chief executive, Samir Brikho, there is absolutely nothing to worry about. Indeed, he is so confident about the company's future that he does not see any risk for the next six or seven years.

Amec issued a trading statement yesterday saying that 2008 Ebitda margin expectations had edged up to 6.5 per cent from 6 per cent. Net cash will exceed £600m, which will enable the group to "make selective acquisitions".

The stock has performed well since dipping as low as 642p in January, but the analysts reckon there is plenty more to come. Those at Merrill Lynch say that trading at 8.3 times EV/Ebitda, Amec operates at an 11 per cent discount to UK-based oil services companies. The analysts reckon the shares are on their way to 1030p, and investors should buy now. They largely agree with Mr Brikho's risk assessment, saying, "there is currently a wide gap between the industry's cash generation [$65 to $140 a barrel] and investment basis [$40 to $60 a barrel], it would take a dramatic fall in oil prices, in our view, to see industry spending patterns change significantly".

The company itself does not like commenting on the share price, however it does get a bit hot under the collar about a note from Seymour Pierce, dismissing it as uninformed. The analysts say that while the company has done well in recent years, that performance is already priced into the stock and the shares do not have any capacity left.

There are not many sectors that are performing like oil. As other markets suffer, so more buyers will be attracted to the black stuff and companies that operate in the oil market. There is more room for growth. Buy.

Galliford Try

Our view: Cautious hold

Share price: 32.5p(+4.75p)

Yes, ok, Galliford Try is a builder, but before readers move straight down to the next piece assuming that anything connected with building is toxic, investors will be interested to learn that the group's stock leapt 14.6 per cent by yesterday's close. The shares spiked after an upbeat trading statement, which said that full-year profits will be in line with forecasts, at no less than £60m.

The obvious point to note is that this is in stark contrast to the rest of the sector. The press is full of premature obituaries for the likes of Taylor Wimpey and Barratt Development. However, this presents an opportunity for investors, say watchers at Numis. They agree that the sector is "terminally ill" but management's strategy of running the company for cash is "proving successful".

Despite Numis ascribing no value to the housebuilding operation, they say that, "putting zero value on housing, construction on 8 times and affordable housing on 10 times (in line with our concerns that new build here could be vulnerable) gets us to 60p, still 82 per cent above the current share price".

All fair enough, but before investors get too carried away, remember the building sector is close to imploding, and even Galliford's chief executive, Greg Fitzgerald, says that things are getting tougher in house building, but points out that the market misses the fact that the company is a much bigger contractor. There will be no increase in dividend, and margins will be hit by the market.

Experts at Merrill Lynch go further, arguing thatpre-tax profit this year will be £60m, resulting in earnings per share of 11.1p, changing to £39m and 7.4p next year respectively. Cautious hold.

Phytopharm

Our view: Hold

Share price: 20.25p (-0.25p)

There is a plethora of small drugs companies spending lots of money developing what they hope will be the next blockbuster cure for a nasty disease. The problem is that often they raise money to put the treatment through the first few trials and then run out towards the end of the process.

That is why analysts at KBC say Phytopharm, which issued a positive trading statement yesterday, is different. The group makes an appetite suppressant, Hoodia, which is due to be used in Unilever's Slim Fast dieting products; the group hopes that this will fund research for its other treatments for the likes of Parkinson's.

UK biotech groups do not have a history of doing well for shareholders. Some do eventually come good, usually by being bought by one of the pharma giants. The only companies that ever do well have plenty of cash. With its Unilever tie-up, Phytopharm hopes to join those ranks. KBC says Hoodia has a 50 per cent chance of phase three trial success, which has already been funded. Hold.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Compliance Assistant

£13000 per annum: Recruitment Genius: This Pension Specialist was established ...

Ashdown Group: Market Research Executive

£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...

Recruitment Genius: Technical Report Writer

£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...

MBDA UK Ltd: Indirect Procurement Category Manager

Competitive salary & benefits!: MBDA UK Ltd: MBDA UK LTD Indirect Procurement...

Day In a Page

Isis hostage crisis: Militant group stands strong as its numerous enemies fail to find a common plan to defeat it

Isis stands strong as its numerous enemies fail to find a common plan to defeat it

The jihadis are being squeezed militarily and economically, but there is no sign of an implosion, says Patrick Cockburn
Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action

Virtual reality: Seeing is believing

Virtual reality thrusts viewers into the frontline of global events - and puts film-goers at the heart of the action
Homeless Veterans appeal: MP says Coalition ‘not doing enough’

Homeless Veterans appeal

MP says Coalition ‘not doing enough’ to help
Larry David, Steve Coogan and other comedians share stories of depression in new documentary

Comedians share stories of depression

The director of the new documentary, Kevin Pollak, tells Jessica Barrett how he got them to talk
Has The Archers lost the plot with it's spicy storylines?

Has The Archers lost the plot?

A growing number of listeners are voicing their discontent over the rural soap's spicy storylines; so loudly that even the BBC's director-general seems worried, says Simon Kelner
English Heritage adds 14 post-war office buildings to its protected lists

14 office buildings added to protected lists

Christopher Beanland explores the underrated appeal of these palaces of pen-pushing
Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

Human skull discovery in Israel proves humans lived side-by-side with Neanderthals

Scientists unearthed the cranial fragments from Manot Cave in West Galilee
World War Z author Max Brooks honours WW1's Harlem Hellfighters in new graphic novel

Max Brooks honours Harlem Hellfighters

The author talks about race, legacy and his Will Smith film option to Tim Walker
Why the league system no longer measures up

League system no longer measures up

Jon Coles, former head of standards at the Department of Education, used to be in charge of school performance rankings. He explains how he would reform the system
Valentine's Day cards: 5 best online card shops

Don't leave it to the petrol station: The best online card shops for Valentine's Day

Can't find a card you like on the high street? Try one of these sites for individual, personalised options, whatever your taste
Diego Costa: Devil in blue who upsets defences is a reminder of what Liverpool have lost

Devil in blue Costa is a reminder of what Liverpool have lost

The Reds are desperately missing Luis Suarez, says Ian Herbert
Ashley Giles: 'I'll watch England – but not as a fan'

Ashley Giles: 'I'll watch England – but not as a fan'

Former one-day coach says he will ‘observe’ their World Cup games – but ‘won’t be jumping up and down’
Greece elections: In times like these, the EU has far more dangerous adversaries than Syriza

Greece elections

In times like these, the EU has far more dangerous adversaries than Syriza, says Patrick Cockburn
Holocaust Memorial Day: Nazi victims remembered as spectre of prejudice reappears

Holocaust Memorial Day

Nazi victims remembered as spectre of prejudice reappears over Europe
Fortitude and the Arctic attraction: Our fascination with the last great wilderness

Magnetic north

The Arctic has always exerted a pull, from Greek myth to new thriller Fortitude. Gerard Gilbert considers what's behind our fascination with the last great wilderness